Together with a case report of an individual with STK11/KRAS co-mutated advanced lung cancer with near complete response to pembrolizumab and platinum-doublet therapy (45), these data suggest that STK11 mutation should not be used as a strict exclusion criterion for immune checkpoint blockade in NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.